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1. Introduction 
Cryptococcus neoformans is an encapsulated yeast first described in 1894, whose infection can 
induce a wide spectrum of clinical manifestations that range from a harmless colonization of 
the airways and asymptomatic infection to meningitis or disseminated disease.  
Virulence probably plays a relatively small role in the outcome of this infection: the crucial 
factor is the immune status of the host. The most serious infections usually develop, in fact, 
in patients with defective cell-mediated immunity, for example those with AIDS, organ 
transplantation, reticuloendothelial malignancy, corticosteroid treatment and sarcoidosis, 
but not in subjects with neutropenia or immunoglobulin deficiency. Cryptococcosis has 
shown an increasing incidence over the last decades, mainly because of the AIDS pandemic, 
and still represents a major life-threatening fungal infection in these patients. 
2. Mycology 
Of the more than 50 species that comprise the genus Cryptococcus, human disease is 
primarily associated with C. neoformans and C. gattii. These two species, once considered as 
two varieties of C. neoformans, include five serotypes based on antigenic specificity of the 
capsular polysaccharide; serotypes A, D, and AD (C. neoformans), and serotypes B and C (C. 
gattii). Genome analyses demonstrate that serotypes A and D are actually distinct strains, 
respectively called C. neoformans var. grubii and C. neoformans var. neoformans. 
C. neoformans forms round, yeast like cells, 3-6 µm in diameter, which are surrounded by a 
polysaccharide capsule when the yeast is present in the host and in certain culture media; 
colonies are smooth, convex and they grow in solid media at 20-37°C. 
The characteristics that allow identification of C. neoformans include microscopical 
appearance, biochemical features (such as the use of creatinine as a nitrogen source, the 
production of melanine, etc.) and the ability to grow at 37°C; in fact, most of 
nonpathogenetic Cryptococcus strains are not able to grow at this temperature. 
3. Epidemiology 
C. neoformans occurs mainly in immune-impaired subjects, can be recovered in high 
concentrations in pigeon faeces and bird nests, and is distributed worldwide, with different 






involve serotype A (C. neoformans var. grubii), which is reported especially in patients living 
in low-income countries, whereas, in Western areas, it represents a clinical problem mainly 
in late presentation HIV-infected patients and is a marker of poor access to health care. On 
the other hand, serotype D (C. neoformans var. neoformans) is predominantly found in 
Western Europe and its infection is uncommon in the rest of the world.  
C. gattii (serotypes B and C) causes 70-80% of Cryptococcal infections among 
immunocompetent hosts and can be isolated from certain species of eucalyptus trees and 
from the air beneath them. Infection by these strains is mainly common in tropical and 
subtropical areas, where the clinical disease occurs sporadically. However, a recent outbreak 
(1999-2003), involving patients with apparently normal immune system, was reported in 
some areas of Canada and Northwest US. 
The incidence of Cryptococcal infection does not significantly differ in relation to age, race 
or occupation. 
Since the mid 1980s, most Cryptococcal disease has occurred in patients with AIDS. The 
overall incidence (5-10% of patients with AIDS in Europe and US) decreased after the 
availability of highly active antiretroviral therapy (HAART). However, cryptococcosis still 
causes death in 15-44% of all patients with AIDS in sub-Saharan Africa and remains one of 
the most common AIDS-defining illnesses in some other areas, such as India, Brazil and 
Thailand.  
4. Pathophysiology 
Cryptococcal infection develops both in animals and humans, but neither animal-to-animal, 
animal-to-human transmission nor person-to-person direct respiratory transmission has been 
documented. The organism is primarily transmitted via the respiratory route. Humans can get 
Cryptococcal infection by inhalation of airborne fungi which are spread from the sources 
mentioned above. Following inhalation, the yeast spores are deposited into the pulmonary 
alveoli, where they are phagocytized by alveolar macrophages. Encapsulated yeasts, however, 
are often resistant to phagocytosis, because of the antiphagocytic and immunosuppressive 
properties of the polysaccharidic capsule, which is able to inhibit the recognition of the yeast 
by phagocytes and the leukocyte migration into the area of fungal replication. 
The host response to Cryptococcal infection involves both cellular and humoral components, 
including natural killer cells, T-lymphocytes, macrophages and anti-Cryptococcal antibodies, 
which enhance the cell-mediated immune response to the organism. 
C. neoformans infection is usually characterized by little or absent necrosis or organ 
dysfunction until late in the disease; the typical lesion consists of a cystic cluster of yeasts 
with no well-defined inflammatory response and well-formed granulomas are generally 
absent. 
The initial pulmonary Cryptococcal infection is usually asymptomatic; in immunocompetent 
hosts the infection can be cleared, contained as latent infection or cause a disease limited to the 
lungs, inducing development of a pneumonia with poorly defined interstitial nodules. In 
contrast, in immunosuppressed patients, especially those with defects in the function of T cells, 
the infection can progress to a meningitis and/or a disseminated disease, which usually is the 






patients, cryptococci disseminate widely and may infect any organ, most frequently the central 
nervous system (CNS), but also bones, prostate, eyes and skin. 
5. Clinical 
The CNS is the main site of Cryptococcal disease in both immunocompetent and 
immunocompromised hosts. The infection usually involves both the meninges and the 
brain, causing a diffuse, usually subacute or chronic disease. 
Immunocompetent hosts may present with either meningitis or, more frequently than 
immunocompromised hosts, with cryptococcomas, which often manifest with focal 
neurologic defects. 
The clinical presentation and the course of Cryptococcal meningitis vary according to the 
underlying medical conditions and immune status of the host: the most common symptoms 
are headache, altered mental status (personality changes, memory loss, reduced level of 
consciousness, confusion, lethargy, up to coma), nausea and vomiting (often associated with 
increased intracranial pressure) and cranial nerves paralysis. Other findings, less frequently 
observed, may include ataxia, aphasia, hearing defects and choreoathetoid movements. 
Ocular symptoms such as blurred vision, photophobia or diplopia may result from 
arachnoiditis, papilledema, optic nerve neuritis or chorioretinitis. 
Physical findings, such as fever and stiff neck, are less common because of the limited 
inflammatory response induced by the encapsulated yeasts. . Some HIV positive patients 
may have minimal or nonspecific symptoms at presentation and may often be afebrile; this 
lack or aspecifity of symptoms contribute to delayed diagnosis. 
Dementia is a potential sequela and may indicate the presence of hydrocephalus as a late 
complication. 
In the case of CNS disease, Cryptococcal lesions should be carefully searched in other body 
sites, considering that, especially in AIDS patients, virtually any organ can be involved. In 
particular, a pneumonia without peculiar features (interstitial patterns or basal unilateral 
infiltrates are frequently observed) and skin lesions mimicking molluscum contagiosum are 
frequently observed.  
6. Diagnosis  
6.1 Laboratory studies 
Even with widespread disease, the routine laboratory tests (e.g. leukocyte count, 
haematocrit, erythrocyte sedimentation rate) may yield normal results.  
Evaluation of cerebral spinal fluid (CSF) is essential in diagnosing CNS disease, usually 
showing depressed CSF glucose concentrations, mild elevated protein concentrations and 
leukocyte counts of 20/µL or higher, with a lymphocyte predominance. The CSF can be 
normal at times, such as in AIDS patients with inadequate inflammatory response or in 
persons with early infection.  
It is also important to evaluate the CSF opening pressure, because elevated values (more 






prognosis, requiring drainage of CSF to reduce the pressure to 200 mmH2O or lower. Prior 
to removal of CSF, CT scanning or MRI should be performed to exclude intracranial masses 
that could result in cerebral herniation, especially in patients with focal neurological signs. 
6.2 Microbiological investigations  
Etiological diagnosis of Cryptococcal meningitis is obtained by microbiological 
investigations performed on the CSF. 
An India ink preparation is commonly used with CSF to identify the organism by direct 
microscopy and to support a presumptive diagnosis; if performed correctly, 25-50% of 
patients with Cryptococcal meningitis show cryptococci. 
In patients with a negative India ink test result, Cryptococcal meningitis can be diagnosed 
with the highly sensitive and specific Cryptococcal antigen testing in CSF, which it is almost 
invariably detected at high titre in this disease. The test is performed by an 
immunoenzimatic procedure. If a lumbar puncture cannot be performed, testing for serum 
antigen can be useful; this test may also be considered as an initial screening tool to detect 
Cryptococcal infection in HIV positive patients. 
CSF and blood should always be cultured for fungi; CSF culture should be performed from 
three or more centrifuged specimens in Sabouraud dextrose agar. Blood culture results prove 
positive in up to 75% of HIV infected patients; this indicates an extensive infection, in which 
the organism may be observed within peripheral leukocytes or bone marrow macrophages. 
A high Cryptococcal burden at the baseline (as detected by quantitative CSF culture or high 
CSF antigen titre) and an altered mental status are the most important predictors of death. 
6.3 Imaging studies 
Obtaining a CT or MRI of the brain prior to performing a lumbar puncture is important in 
patients who present with focal neurologic deficits or a history suggesting slowly 
progressive meningitis, in order to detect mass lesion that may increase the risk of cerebral 
herniation following a lumbar puncture.  
CT can reveal small, ring-enhancing lesions or non-enhancing ‘pseudocystis’. Both CT 
scanning and MRI can also reveal the presence of hydrocephalus caused by basilar meningitis.  
7. Therapeutical management 
Cryptococcal meningitis and disseminated disease represent severe clinical conditions 
which were invariably fatal prior to the use of amphoterycin B, flucytosine and azoles; in 
fact, without a specific antifungal treatment, mortality rates of 100% have been reported 
within two weeks after clinical presentation in certain HIV-infected populations. The 
availability of such antifungal therapy regimens has lead to a dramatic decrease in the 
mortality. However, the three month mortality rate during a correct management of acute 
Cryptococcal meningoencephalitis still approximates 20%, even in areas where HAART and 
advanced medical care are widely available.  
Treatment regimens are based on a sequence of induction, consolidation and maintenance 






treatment aim to obtain a rapid clearance of cryptococcus by the CNS, whereas maintenance 
therapy is targeted to maintain a stable suppression (latency) of the chronic infection in the 










c-AMB (0,7-1 mg/kg/daily) 










L-AMB (3-4 mg/kg/daily) 
or ABLC (5mg/kg/daily)  
(if there are renal concerns)  





Itraconazole (400 mg daily)a 
or: 
c-AMB (1 mg/kg per week)a 
≥1 yearb 
 
c-AMB or L-AMB or ABLC 
(for flucytosine-intolerant 
patients; doses as above) 
4-6 
weeks 




L-AMB (3-4 mg/kg daily) or 
ABLC (5 mg/kg daily) 









c-AMB (0.7 mg/kg daily) or 
L-AMB (6 mg/kg daily) or 












c-AMB (0.7-1 mg/kg daily)  









L-AMB (3-4 mg/kg daily) or 
ABLC (5 mg/kg daily) 









c-AMB or L-AMB or ABLC 
(for flucytosine-intolerant 
patients; doses as above)  
≥6 weeks   
ABLC, amphotericin B lipid complex; c-AMB, amphotericin B deoxycholate; L-AMB, liposomal 
amphotericin B. a: Inferior to fluconazole. b: Consider discontinuing antifungal therapy after a 
minimum of one year, if following a successful HAART, CD4+ count ≥100 cells/µL and undetectable 
viral load are detected for ≥3 months. 
Adapted from [Perfect JR, Clin Inf Dis 1010;50:291-322] 
Table 1. Antifungal treatment for Cryptococcal meningoencephalitis 
7.1 Management of adverse events 
Antifungal drugs used for Cryptococcal meningitis may induce adverse reaction and 






dependent nephrotoxicity and electrolyte alterations, if treated with amphotericin B; for 
bone marrow suppression and gastrointestinal disturbance, if receiving flucytosine; for 
hepatotoxicity, if fluconazole is administrated. 
7.2 HIV-infected patients 
Induction therapy is based on amphotericin B deoxycholate (c-AMB) plus flucytosine (see 
Table 1 for dosage) for at least two weeks; flucytosine can be administered orally or 
intravenously in severe cases or if oral intake is not possible. This regimen should be 
followed by a consolidation therapy with fluconazole orally for eight weeks.  
In patients with renal function impairment, lipid formulations of amphotericin B, mainly 
represented by amphotericin B lipid complex (ABLC) and liposomal amphotericin B (L-
AMB), appear to be less nephrotoxic and can substitute c-AMB. Lipid formulations of 
amphotericin B can also be used as monotherapy for four to six weeks or in association with 
fluconazole in flucytosine-intolerant patients. 
Alternative consolidation regimens include flucytosine plus fluconazole for six weeks, 
fluconazole alone for 10 to 12 weeks or itraconazole for 10 to 12 weeks, although the results 
of several trials with these therapies are variable and often disappointing. 
Maintenance therapy in HIV-infected patients should be started when CSF Cryptococcal 
culture becomes negative and a substantial clinical improvement is observed; oral fluconazole 
is the most effective therapy, with a very low relapse rate, if compared with regimens based on 
oral itraconazole or intravenous c-AMB. It is considered reasonable to discontinue 
maintenance therapy, if patients have successfully completed a course of initial therapy and, 
following HAART, their CD4+ cell count increase to ≥200/µl for at least three to six months.  
Primary prophylaxis for Cryptococcal disease is not routinely recommended for several 
reasons: its relative infrequency in areas where HAART is available, potential for drug 
toxicity or interactions with concurrent medications, risk of antifungal drug resistance and 
costs. However, according to some studies, a screening strategy (Cryptococcal antigen 
testing) and a prophylaxis may be useful in areas where the availability of HAART is 
limited and cryptococcosis incidence is high. 
7.3 Organ transplant recipient 
Cryptococcosis is the third most common fungal infection among solid organ transplant 
recipients, usually occurring more than one year post-transplant and generally representing 
a reactivation of latent infection; CNS involvement and/or disseminated disease are 
documented in most of these patients. Acquisition of the organism usually occurs via 
inhalation, but the risk of transmission through donor organs or other tissues has also been 
recently described, even if in a few cases. 
Primary induction therapy is based on either L-AMB or ABLC plus flucytosine (see Table 1 
for doses) for at least two weeks, followed by fluconazole for eight weeks as consolidation 
regimen and for additional six to 12 months, at lower dosage, as maintenance therapy. The 
use of c-AMB should be avoided because of the risk of nephrotoxicity, especially with the 







If induction therapy does not include flucytosine, L-AMB should be administrated for at 
least four to six weeks. Moreover, a positive CSF culture result after two weeks of induction 
treatment may indicate a poor outcome and suggests a prolonged induction period with L-
AMB in these patients. 
During cryptococcosis, a careful reduction of the immunosuppressant therapy (slow dose 
decrease over time and/or stepwise elimination of immunosuppressants) should be 
adopted following the initiation of antifungal therapy. Furthermore, reduction of 
corticosteroids should precede that of calcineurin inhibitors, since the latter drugs have a 
direct anti-Cryptococcal activity. 
7.4 Non-HIV infected, non transplant recipients patients 
This represents a heterogeneous category of patients that may include ‘presumably 
immunocompetent hosts’, but also people with different immune defects (such as 
malignancy, connective tissue diseases, severe liver disease and so on).  
Antifungal regimens for these patients are substantially the same as the one mentioned above 
(see Table 1), but there are different opinions about the length of induction therapy: according 
to some authors, in fact, duration of induction phase should be two weeks, while others 
suggest to administrate it for four to six weeks. The great variability of features in patients 
forming this category makes it necessary to adapt the therapeutical management to each case. 
8. Indications for the management of complications 
8.1 Persistence and relapses 
Persistent infection is defined by positive results of CSF cultures after four weeks of effective 
antifungal therapy; relapse is defined by the recovery of cryptococci from a previously 
checked sterile body site and/or the recrudescence of signs/symptoms at the previous site 
of disease after an initial normalization. Most cases of relapse are due to an inadequate 
primary therapy (dose and/or duration) or to the lack of the patient adherence to the 
consolidation or maintenance treatment.  
Restarting induction regimen for a longer course and with a higher dosage may be the first 
approach in these situations, using amphotericin B deoxycholate plus fluconazole in flucytosine 
intolerant patients and high doses of fluconazole plus flucytosine in polyene intolerant patients. 
The possibility of development of antifungal drug resistance should also be checked in 
terms of changes in the MIC from the original isolate: a ≥3-dilution difference, in fact, 
suggests development of direct drug resistance. 
Finally, the use of Voriconazole or Posaconazole as salvage therapy should be considered in 
cases resistant to the first-line antifungal agents. However, the frequent interactions of these 
agents with several antiretroviral drugs should be carefully considered in HIV-infected 
patients. In this regard, the use of therapeutic drug monitoring of the plasma concentrations 
of these agents may represent a useful tool in clinical practice. 
8.2 Elevated CSF pressure 
Control of CSF pressure is one of the most important determinants in the outcome of 






in the CNS and with increased morbidity and mortality rates. This association is valid for 
most HIV-infected patients (there is lack of data about this complication in non-HIV patients 
with Cryptococcal meningitis), so it is very important to measure the initial opening 
pressure during the first lumbar puncture. If there is persistent pressure elevation (≥25 cm of 
CSF) and symptoms, lumbar puncture should be repeated daily, until CSF pressure and 
symptoms have been stabilized for ≥2 days, considering temporary percutaneous lumbar 
drains or ventriculostomy if repeated daily lumbar punctures are required. 
8.3 Cryptococcoma  
Large cryptococcomas should be treated with a combination of antifungal therapy and early 
surgical removal, as response to antifungal drugs only is poor. Multiple lesions require a 
prolonged induction/eradication therapy. Corticosteroids may be required if there is a 
substantial surrounding oedema, especially in the presence of neurological deficits. 
Moreover, a nonresponsive brain mass in severely immunosuppressed patients may also 
suggest the presence of a second pathogen or a tumour. 
8.4 IRIS 
Immune reconstitution inflammatory syndrome (IRIS) consists of a paradoxical worsening 
of the clinical manifestations or the course of the Cryptococcal disease in spite of an 
appropriate antifungal therapy and an apparent microbiological efficacy of the latter. IRIS is 
interpreted as an exuberant inflammatory reaction of the host at the sites of Cryptococcal 
infection, subsequent to a rapid improvement in the cellular immunity; for example, IRIS 
may occur in AIDS patients following introduction of HAART and the restoration of 
pathogen-specific CD4+ cells. 
Risk factors for developing IRIS include: severe Cryptococcal disease (high fungemia), HIV 
infection, extremely low baseline CD4+ cell count, no previous antiretroviral therapy, lack of 
CSF sterilization at week two of therapy, introduction of HAART during the early part of 
antifungal induction therapy and rapid decrease in the HIV viral load in response to HAART. 
If IRIS occurs, it is not recommended to modify antifungal therapy, neither to administrate 
any specific treatment for minor manifestations, whereas corticosteroids may be required for 
major complications, such as severe CNS inflammation. In order to reduce the risk of 
developing IRIS, according to the principal current guidelines, introduction of HAART 
should be delayed for two to 10 weeks after the starting of antifungal therapy. 
9. Suggested treatment in special clinical situations 
9.1 Pregnant women 
If Cryptococcal meningitis occurs during pregnancy it is often severe because of the 
immunological alterations associated with this event. c-AMB or L-AMB should be 
administrated as induction therapy, while the use of flucytosine (pregnancy category C) 
must be considered in relationship to benefit versus risk. Fluconazole (pregnancy category 
C) must be preferably started after delivery and should be avoided in the first trimester. 
During the last two trimesters the possible benefits following fluconazole use should be 








Cryptococcosis in children is less frequent than in adults and it is associated with some 
underlying conditions, such as primary immune defects or certain haematological 
malignancies, peculiar to childhood, and to common risk factors for both adults and 
children (e.g. AIDS, transplant recipients). 
Induction and consolidation therapy for children is based on the use of c-AmB plus 
flucytosine for two weeks, followed by fluconazole for eight weeks (10-12 mg/kg daily); for 
AmB-intolerant patients it is possible to administrate either L-AmB or ABLC. Maintenance 
therapy is based on the use of fluconazole (6 mg/kg daily). 
The optimal dosing and duration of therapy for children with cryptococcosis, however, have 
not been precisely determined because of the lack of literature data concerning this matter. 
For the non–HIV-infected, non-transplant population, treatment dose and length schedules 
similar to that indicated above for adults is prescribed (except for fluconazole dose, which is 
modified as explained above).  
9.3 Resource – Limited health care environment 
In many areas of the world with high incidence of cryptococcosis the most effective 
antifungal drugs are often not available and adjustments in the management of patients 
with Cryptococcal disease often become necessary. The recommendations concerning 
therapeutical approach in these settings include: 
- When flucytosine is not available, induction therapy is represented by c-AmB with or 
without fluconazole for two weeks, followed by fluconazole as consolidation therapy 
for eight weeks and as maintenance therapy until immune reconstitution. 
- When a polyene is not available, induction therapy is based on fluconazole for at least 
10 weeks or until CSF culture results are negative, followed by 
consolidation/maintenance therapy with the same drug, at a lower dosage. 
- When a polyene is not available but flucytosine is available, induction therapy is 
represented by fluconazole plus flucytosine for two to 10 weeks, followed by 
maintenance therapy with fluconazole. 
- With use of primary fluconazole therapy for induction, both primary or secondary drug 
resistance of the isolate may be an issue, and MIC testing is advised; for azole-resistant 
strains, administer c-AmB until CSF, blood, and/or other sites are sterile. 
9.4 C. gattii infection 
Induction, consolidation and suppressive treatment are the same as for C. neoformans. A 
delayed response to treatment frequently occurs. A radiology follow-up focused on 
cryptococcoma and hydrocephalus is needed as these conditions are often observed in 
patients with C. gattii infection, as described above. For very large and multiple 
cryptococcomas, a combination of cAmB and flucytosine therapy for four to six weeks 
should be considered, followed by fluconazole for six to 18 months, depending on whether 
surgery was performed. Neurosurgical intervention must be considered if there is 
compression of vital structures, failure to reduce the size of cryptococcoma after four weeks 







Fig. 1. Brain magnetic resonance of an AIDS patient with Cryptococcal meningitis, 
highlighting dilatation of the perivascular (Virchow-Robin) spaces  
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